Yeah I saw the Evaluatepharma article and it was surprisingly incorrect factually. They probably would not have been so dismissive had it been a US analyst covering the stock.
They were not comparing apples to apples. They talked about a deal value estimated by Bell Potter for a worldwide license vs. the actual value NEU obtained for just US license, saying Bell Potter set expectations too high..
Once NEU ultimately licenses out Ex-US rights, the Acadia deal value plus the Ex-US deal value may still be close to or higher than what Bell Potter was estimating in 2018.
Yeah I saw the Evaluatepharma article and it was surprisingly...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.622B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $6.431M | 315.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1024 | $20.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.53 | 285 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |